Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
AssigneeDana-Farber Cancer Institute, Inc.
InventorRobert M. Bachoo
Life of this patent
Estimating the term…
Abstract
A material comprising a plurality of closed cells is provided, the space within each cell being substantially evacuated. This may be achieved by sealing a dimpled film to a sealing film in a vacuum so that each dimple is closed while under vacuum to form an evacuated closed cell.
Claims34
A method of assessing whether a subject is afflicted with a neurological disease, disorder or condition, the method comprising comparing:
- a) the amount and/or activity of at least one marker in a subject sample, wherein the at least one marker is selected from the group consisting of the markers listed in Table 2, and
- b) the normal amount and/or activity of at the least one marker in a control sample from a subject not afflicted with a neurological disease, disorder or condition,
- wherein modulation of the amount and/or activity of the at least one marker in the subject sample compared to the normal amount and/or activity is an indication that the subject is afflicted with a neurological disease, disorder or condition.
(canceled)
(canceled)
(canceled)
(canceled)
16-21. (canceled)
A method of selecting a composition capable of modulating a symptom of neurological disease, disorder or condition, the method comprising:
- a) providing a sample comprising astrocytes;
- b) contacting said sample with a test compound;
- and
- c) determining the ability of the test compound to modulate the amount and/or activity of at least one marker, wherein the marker is selected from the group consisting of the markers listed in Table 2;
- and
- thereby identifying a composition capable of modulating a symptom of a neurological disease, disorder or condition.
A method of treating a subject afflicted with a neurological disease, disorder or condition comprising administering to the subject a therapeutically effective amount of a compound which modulates the amount and/or activity of a gene or protein corresponding to at least one marker listed in Table 2, thereby treating a subject afflicted with a neurological disease, disorder or condition.
30-44. (canceled)
A kit for assessing whether a subject is afflicted with a neurological disease, disorder or condition, the kit comprising reagents for assessing the amount and/or activity of at least one marker selected from the group consisting of the markers listed in Table 2.
47-53. (canceled)
A recombinant vector comprising an astrocyte-specific promoter operably linked to a Cre recombinase.
56-57. (canceled)
60-72. (canceled)
Dependencies are inferred from the claim text.